Stockscreener 앱 받기
11.95
0.75%
-0.09
Greenwich Lifesciences Inc 주식(GLSI)의 최신 뉴스
Short Interest in Greenwich LifeSciences, Inc. (NASDAQ:GLSI) Rises By 5.1% - MarketBeat
Greenwich LifeSciences, Inc. (NASDAQ:GLSI) Short Interest Up 5.1% in January - MarketBeat
Research Analysts Set Expectations for GLSI FY2024 Earnings - MarketBeat
Learn to Evaluate (GLSI) using the Charts - Stock Traders Daily
HC Wainwright Reiterates Buy Rating for Greenwich LifeSciences (NASDAQ:GLSI) - MarketBeat
What is HC Wainwright’s Estimate for GLSI FY2024 Earnings? - Defense World
Greenwich LifeSciences reports progress in FLAMINGO-01 trial - MSN
Greenwich LifeSciences (NASDAQ:GLSI) Given “Buy” Rating at HC Wainwright - Defense World
SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Greenwich LifeSciences, Inc. (NASDAQ: GLSI) - PR Newswire
Greenwich LifeSciences Provides Update on Open Label HLA Data from FLAMINGO-01 - GlobeNewswire
Greenwich LifeSciences reports progress in FLAMINGO-01 trial By Investing.com - Investing.com UK
Clinical Trial Success: Greenwich's Breast Cancer Immunotherapy Achieves Critical Patient Milestone - StockTitan
Greenwich LifeSciences: Long Time To Results, Little Cash, Hard To Recommend (GLSI) - Seeking Alpha
(GLSI) Technical Pivots with Risk Controls - Stock Traders Daily
EMA approves addition of sites to Greenwich LifeSciences’ breast cancer trial - Yahoo Finance
Greenwich LifeSciences Gets EU Drug Regulator Approval to Add Sites to GLSI-100 Late-Stage Trial - Marketscreener.com
Greenwich LifeSciences stock gains on approval to add additional sites to Flamingo-01 in Europe - MSN
Greenwich LifeSciences Approved to Add Additional Sites to FLAMINGO-01 in Europe - GlobeNewswire
Major Breakthrough: Cancer Prevention Trial Goes Europe-Wide as Top Medical Centers Join Forces - StockTitan
Greenwich LifeSciences Announces Activation of Flamingo-01 in Poland - GlobeNewswire
Greenwich LifeSciences Expands Phase III Breast Cancer Trial Across Poland - StockTitan
How to Take Advantage of moves in (GLSI) - Stock Traders Daily
Greenwich LifeSciences gains after GP2 commercial manufacturing update - MSN
Barclays PLC Has $123,000 Stake in Greenwich LifeSciences, Inc. (NASDAQ:GLSI) - Defense World
Bullish Greenwich LifeSciences Insiders Loaded Up On US$3.39m Of Stock - Yahoo Finance
Greenwich LifeSciences Announces Additions of Harvard and Johns Hopkins to Flamingo-01 - GlobeNewswire
Harvard, Johns Hopkins Join Greenwich LifeSciences' Phase III Breast Cancer Vaccine Trial - StockTitan
Greenwich LifeSciences stock gains on GP2 update (GLSI) - Seeking Alpha
Greenwich LifeSciences Provides Update on Commercial Manufacturing - GlobeNewswire
Greenwich LifeSciences Achieves Major Manufacturing Milestone for Breast Cancer Immunotherapy GP2 - StockTitan
Glancy Prongay & Murray LLP Announces Investigation of Greenwich LifeSciences, Inc. (GLSI) - Marketscreener.com
Long Term Trading Analysis for (GLSI) - Stock Traders Daily
Greenwich LifeSciences Announces Partnership with GBG in Germany for Flamingo-01 - GlobeNewswire
Greenwich LifeSciences expands trial sites in Germany - Investing.com India
Greenwich Lifesciences Announces Partnership with GBG in Germany for Flamingo-01 - Marketscreener.com
Greenwich LifeSciences Expands Phase III Cancer Trial with Major German Research Network - StockTitan
Greenwich LifeSciences CEO acquires $31,275 in common stock By Investing.com - Investing.com Australia
Greenwich LifeSciences CEO acquires $31,275 in common stock - Investing.com India
Greenwich LifeSciences, Inc. (NASDAQ:GLSI) CEO Snehal Patel Buys 2,500 Shares - MarketBeat
Insider Buying: Snehal Patel Acquires Additional Shares of Green - GuruFocus.com
Greenwich LifeSciences Partners with Unicancer Expanding Flamingo-01 into France - The Manila Times
Greenwich LifeSciences Expands Phase III Breast Cancer Trial Across France with Unicancer Network - StockTitan
Geode Capital Management LLC Raises Stock Holdings in Greenwich LifeSciences, Inc. (NASDAQ:GLSI) - Defense World
Barclays PLC Increases Position in Greenwich LifeSciences, Inc. (NASDAQ:GLSI) - Defense World
Greenwich Lifesciences CEO Snehal Patel buys $39,391 in stock By Investing.com - Investing.com Australia
0.27%
3.05%
자본화:
|
볼륨(24시간):